US 8298525
Method of treating multiple sclerosis with interferon-beta and an IL-2R antagonist
granted A61KA61K2039/505A61K2039/54
Quick answer
US patent 8298525 (Method of treating multiple sclerosis with interferon-beta and an IL-2R antagonist) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon Oct 25 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America as Represented by the Secretary of the Department of Health and Human Services
- Grant date
- Tue Oct 30 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 25 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K31/7052